FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group
FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group